Tuesday 31 March 2015

Chinese homozygous Machado–Joseph disease/SCA3: a case report



Short Communication



Abstract



A young Chinese male patient was identified as homozygous for Machado–Joseph disease (MJD)/spinocerebellar ataxia type 3. This patient had a 4-year medical history mainly presenting severe ataxia, abnormal eye movement and pyramidal signs. Magnetic resonance imaging of the brain and cervical spinal cord revealed no obvious abnormality despite the severe symptoms and the findings of an electromyogram. However, brainstem auditory evoked potential indicated peripheral impairment and visual evoked potential indicated central impairment of his visual pathways. Molecular diagnosis revealed the pattern of CAG repeat units of this patient was 71/71. This case demonstrates that homozygosity for MJD enhances the clinical severity of the disease, which suggests that genetic education is of great importance.




------------------------------------------
Journal of Human Genetics 60, 157-160 (March 2015) | doi:10.1038/jhg.2014.117, Chinese homozygous Machado–Joseph disease (MJD)/SCA3: a case report, Sheng Zeng, Junsheng Zeng, Miao He, Xianfeng Zeng, Yao Zhou, Zhen Liu, Hong Jiang, Beisha Tang and Junling Wang







Monday 30 March 2015

BioBlast Pharma announces positive results of Its Cabaletta platform in SCA3



BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company announced today positive in vivo proof-of-concept results for Cabaletta for Spinocerebellar Ataxia Type 3 (also known as SCA3 or Machado Joseph disease). Results were presented at the International Ataxia Research Conference held in Windsor UK, March 25-28, 2015.


Studies



Cabaletta was tested in two different animal models of the disease:
  • In a transfected mouse model, Cabaletta demonstrated efficacy in reducing the pathological cellular aggregates that are the root cause of the extensive nerve damage characteristic of SCA3. In a series of experiments, Cabaletta reduced the protein aggregations that are potentially toxic to neural cells, and reduced the biomarkers indicative of ubiquitin-imminent cell death. Immunohistochemistry studies corroborated this effect by demonstrating prevention of Darpp-32 loss in treated animal cells, a sensitive biomarker of neural damage. 
  • In a transgenic mouse model, treatment with Cabaletta was effective in preventing and preserving neural functions in multiple tests including the Rotarod and swimming tests. 


Colin Foster, BioBlast’s President and CEO commented: “Our in vivo proof-of-concept studies demonstrate Cabaletta’s efficacy in reducing Ataxin3 aggregates, reducing neural markers for neural damage and preventing typical phenotypic deterioration in animal models. As a whole, this is powerful support for our ongoing SCA3 Phase 2 clinical trial program underway in Israel. We anticipate expanding the number of SCA3 clinical study centers later this year.


“There are approximately two dozen diseases that Cabaletta may address, given a common disease-causing mechanism related to intracellular and intranuclear protein aggregation. With Cabaletta, we have previously reported on our ongoing oculopharyngeal muscular dystrophy (OPMD) Phase 2/3 multicenter clinical trial and our preclinical work in spino bulbar muscular atrophy. Today, given the SCA3 proof-of-concept results, we share the fervent hopes of the many SCA3 patients waiting anxiously for a treatment for this devastating disease.”


About Cabaletta



Cabaletta is BioBlast’s proprietary intravenous (IV) solution of trehalose, a disaccharide, known for its capabilities in stabilizing intracellular and intranuclear proteins and enhancing autophagy.
About Spinocerebellar Ataxia Type 3 (SCA3 or Machado Joseph Disease)


SCA3, also known as Machado Joseph disease, is the most common among the cerebellar ataxias, which are a group of genetic diseases that are characterized by gait and movement disorders memory deficits, spasticity, difficulty with speech and swallowing, weakness in arms and other muscular anomalies. Symptoms can begin in early adolescence and get worse over time. Eventually SCA3 leads to paralysis and severe disability. The disease typically appears in the third or fourth decades of life and is associated with early death, on average within 15-20 years of diagnosis. There is currently no approved treatment for the disease.


About BioBlast



BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.


The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.



Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss making further progress toward providing a therapy to help SCA3 patients, that our platforms potentially offer solutions for several diseases that share the same biological pathology, including approximately two dozen diseases in the case of our Cabaletta product candidate, or when we discuss expanding the number of SCA3 clinical studies and timing of such expansion. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results would not be interpreted differently in light of additional research and clinical and preclinical trials results. Because such statements deal with future events and are based on


BioBlast Pharma Ltd.’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Bio Blast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading “Risk Factors” in BioBlast Pharma’s prospectus dated July 30, 2014 filed with the Securities and Exchange Commission (“SEC”) and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.


--------------------------------------------


Thursday 19 March 2015

Lazarillo-related Lipocalins confer long-term protection against SCA1 degenerationcontributing to optimize selective autophagy



Research article


Abstract


A diverse set of neurodegenerative disorders are caused by abnormal extensions of polyglutamine (poly-Q) stretches in various, functionally unrelated proteins. A common feature of these diseases is altered proteostasis. Autophagy induction is part of the endogenous response to poly-Q protein expression. However, if autophagy is not resolved properly, clearance of toxic proteins or aggregates cannot occur effectively. Likewise, excessive autophagy induction can cause autophagic stress and neurodegeneration. The Lipocalins ApoD, Glial Lazarillo (GLaz) and Neural Lazarillo (NLaz) are neuroprotectors upon oxidative stress or aging. In this work we test whether these Lipocalins also protect against poly-Q-triggered deterioration of protein quality control systems.


Results



Using a Drosophila retinal degeneration model of Type-1 Spinocerebellar Ataxia (SCA1) combined with genetic manipulation of NLaz and GLaz expression, we demonstrate that both Lipocalins protect against SCA1 neurodegeneration. They are part of the endogenous transcriptional response to SCA1, and their effect is non-additive, suggesting participation in a similar mechanism. GLaz beneficial effects persist throughout aging, and appears when expressed by degenerating neurons or by retinal support and glial cells. GLaz gain-of-function reduces cell death and the extent of ubiquitinated proteins accumulation, and decreases the expression of Atg8a/LC3, p62 mRNA and protein levels, and GstS1 induction. Over-expression of GLaz is able to reduce p62 and ubiquitinated proteins levels when rapamycin-dependent and SCA1-dependent inductions of autophagy are combined. In the absence of neurodegeneration, GLaz loss-of-function increases Atg8a/LC3 mRNA and p62 protein levels without altering p62 mRNA levels. Knocking-down autophagy, by interfering with Atg8a or p62 expression or by expressing dominant-negative Atg1/ULK1 or Atg4a transgenes, rescues SCA1-dependent neurodegeneration in a similar extent to the protective effect of GLaz. Further GLaz-dependent improvement is concealed.

Conclusions


This work shows for the first time that a Lipocalin rescues neurons from pathogenic SCA1 degeneration by optimizing clearance of aggregation-prone proteins. GLaz modulates key autophagy genes and lipid-peroxide clearance responsive genes. Down-regulation of selective autophagy causes similar and non-additive rescuing effects. These data suggest that SCA1 neurodegeneration concurs with autophagic stress, and places Lazarillo-related Lipocalins as valuable players in the endogenous protection against the two major contributors to aging and neurodegeneration: ROS-dependent damage and proteostasis deterioration.




-----------------------------
Molecular Neurodegeneration 2015, 10:11 doi:10.1186/s13024-015-0009-8,
Lazarillo-related Lipocalins confer long-term protection against type I Spinocerebellar Ataxia degeneration contributing to optimize selective autophagy, Manuela del CaƱo-Espinel†, Judith R Acebes, Diego Sanchez† and Maria D Ganfornina*

*Corresponding author: Maria D Ganfornina opabinia@ibgm.uva.es
† Equal contributors
Published: 19 March 2015

Thursday 12 March 2015

Many paths to degeneration for neurons - SCA1


Adult neurons are touchy things. Too much protein can throw them off course, resulting in neurodegeneration.


After showing how mutant ATAXIN1 (the protein associated with the neurodegenerative disorder spinocerebellar ataxia 1) cannot fold and be discarded properly, resulting in malfunctioning neurons, Dr. Huda Zoghbi and her colleagues have found an RNA-binding protein called PUMILIO1 that regulates ATAXIN1 levels. Loss of PUMILIO1 activity – as when it is knocked out or lost – increases the amount of normal ATAXIN1 in the cell and, in studies of mice, causes neurodegeneration that mimics that of spinocerebellar ataxia 1 (SCA1).


People and animals that have this disorder first lose balance and then slowly begin to lose the ability to swallow and, in people, speak. Sooner or later, spasticity and paralysis result and eventually the patient dies. However, the disorder spinocerebellar ataxia 1 is fairly rare, occurring in approximately 1 to 2 in 100,000 people. It is inherited dominantly when the faulty protein is mutated. Each child of a person with the disorder has a one in two chance of inheriting the faulty gene and inheriting the disease.


In a report (journal Cell, Zoghbi et al.) it was demonstrated that an RNA-binding protein called PUMILIO1 also regulates levels of the ATAXIN1 protein. When a mouse lacks one copy of the PUMILIO1 gene, the amount of ATAXIN1 increases, starting early in development. The mouse that loses the copy or copies of PUMILIO1 develops symptoms reminiscent of spinocerebellar ataxia 1, loss of motor coordination and degeneration of Purkinje neurons in the cerebellum. Eliminating the copy of the PUMILIO1 gene in mice that already lack a copy of ATAXIN1 reduces the abnormal symptoms and rescues the animals from the disease. 



The researchers postulate that it is essential to maintain precise levels of both proteins – PUMILIO1 and ATAXIN1. If that balance is lost, the animals develop symptoms of the neurodegenerative disease. Mutations that decrease PUMILIO1 levels by 50 percent or increase ATAXIN1 levels by 30 to 50 percent at an early stage in development can cause early onset degeneration of the cerebellum.


“This finding is important. There may be patients who lack a functional copy of PUMILIO1 through a copy number variation or a mutation that inactivates it. Such patients are at risk of early onset neurodegeneration. Patients who have a duplication of ATAXIN1 (an extra copy) are at risk for childhood ataxia,” said Zoghbi, who is also a professor of pediatrics, neuroscience, and neurology at Baylor and a Howard Hughes Medical Institute investigator.


“If we could find a treatment that reduces ATAXIN1 early on, it would be helpful in the long term,” she said. “It gives hope in this disease.”


The findings with PUMILIO1 demonstrate that neurons require just the right amount of the important protein – not too much and not too little.


“It shows that cells in the brain are not tolerant of too much of a normal protein,” she said. “If we can come back and slightly decrease those proteins early in life before the system falters, we may have an effect.”


“For the late onset spinocerebellar ataxia 1, if we could come up with a strategy to find molecules to decrease the mutant ATAXIN1 – no more than 10 to 20 percent – we might be able to relieve the disease,” said Zoghbi.


“This could be important in the study of other neurodegenerative diseases. We don’t know what proteins are involved and what happens in diseases such as Parkinson’s, Alzheimer, amyotrophic lateral sclerosis and similar disorders,” said Gennarino. “For these and other neurodegenerative conditions that do not fit Mendelian categories, it may prove most fruitful to find factors that elevate the levels of the key disease-driving proteins.”

-------------------------------
Others who took part in this work include Ravi K. Singh, Joshua J. White, Antonia De Maio, Kihoon Han, Ji-Yoen Kim, Paymaan Jafar-Nejad, Alberto di Ronza, Hyojin Kang, Layal S. Sayegh, Thomas A. Cooper and Roy V. Sillitoe, all of Baylor; and Harry T. Orr of the Institute for Translational Neuroscience, University of Minnesota at Minneapolis.


Funding for this program came from the National Institute of Neurological Disorders and Stroke (Grant NS27600 to H.Y.Z.) and the RNA In Situ Hybridization, Confocal and Mouse Behavioral Cores at the BCM Intellectual and Developmental Disabilities Research Center (IDDRC; Grant National Institutes of Health/National Institute of Child Health and Human Development Grant HD024064) and (Grant 1R01NS089664-01 to R.V.S.), as well as the Howard Hughes Medical Institute.


------------------------------------------
Baylor College of Medicine News, 713-798-4710 
Houston, TX - Mar 12, 2015
Many paths to degenerate for neurons












After business hours call: (713) 775-6912